Global Alzheimer's Disease Diagnostics Market Size Study, by Diagnostic Technique (Biomarkers, Imaging Techniques, Genetic Testing), by Type (Triage, Diagnosis, Screening), by End-Use, and Regional Forecasts 2022-2032

Description

The Global Alzheimer's Disease Diagnostics Market was valued at approximately USD 7.50 billion in 2023 and is poised to expand at a CAGR of 11.03% over the forecast period 2024-2032. With the prevalence of Alzheimer's disease escalating at an alarming rate, the urgency for early and precise diagnostics has surged dramatically. Advanced diagnostic techniques leveraging biomarkers, imaging technologies, and genetic testing have revolutionized disease detection, enabling early intervention and paving the way for more effective therapeutic strategies. These innovations are not only enhancing the accuracy of Alzheimer's diagnosis but also contributing significantly to drug development and personalized medicine approaches, offering a glimpse into the future of neurology and cognitive health management.

The global market is experiencing robust growth due to a confluence of factors. An aging population, coupled with the increasing burden of neurodegenerative diseases, is amplifying the demand for cutting-edge diagnostic solutions. Additionally, continuous advancements in imaging modalities and biomarker-based diagnostics have heightened the precision of disease identification, leading to improved patient outcomes. Governments and research institutions worldwide are pouring substantial investments into Alzheimer's research, further propelling market expansion. However, the high cost of diagnostic procedures and limited accessibility in emerging economies remain formidable challenges that could impede growth in certain regions.

North America continues to dominate the Alzheimer's Disease Diagnostics Market, owing to well-established healthcare infrastructure, the presence of key industry players, and increasing awareness campaigns about early disease detection. The United States remains a frontrunner, driven by high healthcare expenditures, strong research initiatives, and favorable reimbursement policies. Europe follows closely, benefiting from increased funding for neurodegenerative disease research and the rapid adoption of technologically advanced diagnostic tools. Meanwhile, the Asia Pacific region is expected to exhibit the fastest growth during the forecast period, bolstered by rising healthcare expenditures in China, India, and Japan, an expanding elderly population, and increased investments in precision medicine.

With mounting concerns over Alzheimer's disease and the need for breakthrough innovations in diagnostics, the industry is witnessing a surge in collaborations between biotechnology firms, pharmaceutical giants, and research institutions. These partnerships are focused on refining existing diagnostic approaches and developing novel biomarker-based solutions to enable early disease detection. As the landscape of neurodegenerative disease diagnostics continues to evolve, market players are actively engaging in mergers, acquisitions, and strategic alliances to solidify their positions in this rapidly expanding sector.

Major Market Players Included in This Report Are:

Roche Diagnostics
Siemens Healthineers
GE Healthcare
Thermo Fisher Scientific Inc.
Eli Lilly and Company
Bio-Rad Laboratories, Inc.
Fujirebio Diagnostics, Inc.
Quest Diagnostics Incorporated
PerkinElmer Inc.
C2N Diagnostics
Neurovision Imaging LLC
Quanterix Corporation
Merck KGaA
Medtronic Plc
Agilent Technologies, Inc.

The Detailed Segments and Sub-Segments of the Market Are Explained Below:

By Diagnostic Technique:

Biomarkers
Imaging Techniques
Genetic Testing

By Type:

Triage
Diagnosis
Screening

By End-Use:

Hospitals
Diagnostic Laboratories
Research Institutions
Others

By Region:

North America:

U.S.
Canada

Europe:

UK
Germany
France
Spain
Italy
Rest of Europe

Asia Pacific:

China
India
Japan
Australia
South Korea
Rest of Asia Pacific

Latin America:

Brazil
Mexico

Middle East & Africa:

Saudi Arabia
South Africa
Rest of MEA

Years Considered for the Study:

Historical Year - 2022, 2023
Base Year - 2023
Forecast Period - 2024 to 2032

Key Takeaways:

Market Estimates & Forecasts for 10 years from 2022 to 2032.
Annualized revenues and regional-level analysis for each market segment.
Detailed analysis of geographical landscape with country-level breakdowns of major regions.
Competitive landscape with strategic insights into key industry players.
In-depth evaluation of business strategies and recommendations for future market expansion.
Supply and demand chain analysis to provide a 360-degree market perspective.

Chapter 1. Global Alzheimer's Disease Diagnostics Market Executive Summary

1.1. Global Alzheimer's Disease Diagnostics Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Diagnostic Technique
- 1.3.2. By Type
- 1.3.3. By End-Use
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Alzheimer's Disease Diagnostics Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory Frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Alzheimer's Disease Diagnostics Market Dynamics

3.1. Market Drivers
- 3.1.1. Rising Prevalence of Alzheimer's Disease
- 3.1.2. Technological Advancements in Diagnostic Imaging and Biomarkers
- 3.1.3. Increased Government Funding and Research Initiatives
3.2. Market Challenges
- 3.2.1. High Cost of Diagnostic Procedures
- 3.2.2. Limited Accessibility in Emerging Economies
- 3.2.3. Regulatory and Reimbursement Hurdles
3.3. Market Opportunities
- 3.3.1. Innovation in Biomarker and Genetic Testing
- 3.3.2. Expansion of Diagnostic Infrastructure and Services
- 3.3.3. Strategic Collaborations and Partnerships

Chapter 4. Global Alzheimer's Disease Diagnostics Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Alzheimer's Disease Diagnostics Market Size & Forecasts by Diagnostic Technique 2022-2032

5.1. Segment Dashboard
5.2. Global Alzheimer's Disease Diagnostics Market: Diagnostic Technique Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. Biomarkers
- 5.2.2. Imaging Techniques
- 5.2.3. Genetic Testing

Chapter 6. Global Alzheimer's Disease Diagnostics Market Size & Forecasts by Type 2022-2032

6.1. Segment Dashboard
6.2. Global Alzheimer's Disease Diagnostics Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. Triage
- 6.2.2. Diagnosis
- 6.2.3. Screening

Chapter 7. Global Alzheimer's Disease Diagnostics Market Size & Forecasts by End-Use 2022-2032

7.1. Segment Dashboard
7.2. Global Alzheimer's Disease Diagnostics Market: End-Use Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 7.2.1. Hospitals
- 7.2.2. Diagnostic Laboratories
- 7.2.3. Research Institutions
- 7.2.4. Others

Chapter 8. Global Alzheimer's Disease Diagnostics Market Size & Forecasts by Region 2022-2032

8.1. North America Alzheimer's Disease Diagnostics Market
- 8.1.1. U.S. Alzheimer's Disease Diagnostics Market
  - 8.1.1.1. Diagnostic Technique Breakdown Size & Forecasts, 2022-2032
  - 8.1.1.2. End-Use Breakdown Size & Forecasts, 2022-2032
- 8.1.2. Canada Alzheimer's Disease Diagnostics Market
8.2. Europe Alzheimer's Disease Diagnostics Market
- 8.2.1. U.K. Alzheimer's Disease Diagnostics Market
- 8.2.2. Germany Alzheimer's Disease Diagnostics Market
- 8.2.3. France Alzheimer's Disease Diagnostics Market
- 8.2.4. Spain Alzheimer's Disease Diagnostics Market
- 8.2.5. Italy Alzheimer's Disease Diagnostics Market
- 8.2.6. Rest of Europe Alzheimer's Disease Diagnostics Market
8.3. Asia-Pacific Alzheimer's Disease Diagnostics Market
- 8.3.1. China Alzheimer's Disease Diagnostics Market
- 8.3.2. India Alzheimer's Disease Diagnostics Market
- 8.3.3. Japan Alzheimer's Disease Diagnostics Market
- 8.3.4. Australia Alzheimer's Disease Diagnostics Market
- 8.3.5. South Korea Alzheimer's Disease Diagnostics Market
- 8.3.6. Rest of Asia-Pacific Alzheimer's Disease Diagnostics Market
8.4. Latin America Alzheimer's Disease Diagnostics Market
- 8.4.1. Brazil Alzheimer's Disease Diagnostics Market
- 8.4.2. Mexico Alzheimer's Disease Diagnostics Market
- 8.4.3. Rest of Latin America Alzheimer's Disease Diagnostics Market
8.5. Middle East & Africa Alzheimer's Disease Diagnostics Market
- 8.5.1. Saudi Arabia Alzheimer's Disease Diagnostics Market
- 8.5.2. South Africa Alzheimer's Disease Diagnostics Market
- 8.5.3. Rest of MEA Alzheimer's Disease Diagnostics Market

Chapter 9. Competitive Intelligence

9.1. Key Company SWOT Analysis
- 9.1.1. Roche Diagnostics
- 9.1.2. Siemens Healthineers
- 9.1.3. GE Healthcare
9.2. Top Market Strategies
9.3. Company Profiles
- 9.3.1. Roche Diagnostics
  - 9.3.1.1. Key Information
  - 9.3.1.2. Overview
  - 9.3.1.3. Financial (Subject to Data Availability)
  - 9.3.1.4. Product Summary
  - 9.3.1.5. Market Strategies
- 9.3.2. Siemens Healthineers
- 9.3.3. GE Healthcare
- 9.3.4. Thermo Fisher Scientific Inc.
- 9.3.5. Eli Lilly and Company
- 9.3.6. Bio-Rad Laboratories, Inc.
- 9.3.7. Fujirebio Diagnostics, Inc.
- 9.3.8. Quest Diagnostics Incorporated
- 9.3.9. PerkinElmer Inc.
- 9.3.10. C2N Diagnostics
- 9.3.11. Neurovision Imaging LLC
- 9.3.12. Quanterix Corporation
- 9.3.13. Merck KGaA
- 9.3.14. Medtronic Plc
- 9.3.15. Agilent Technologies, Inc.

Chapter 10. Research Process

10.1. Research Process
- 10.1.1. Data Mining
- 10.1.2. Analysis
- 10.1.3. Market Estimation
- 10.1.4. Validation
- 10.1.5. Publishing
10.2. Research Attributes